CPSH CPS TECHNOLOGIES CORP/DE/ Insider Trading

Director Cavoli buys 2,315 CPSH shares at $3.86; 5th purchase in 6 months with 4-for-4 well-timed 90d outcomes, amid 54.3% annual revenue growth.

Cavoli's purchase of 2,315 shares at $3.86 extends a sustained accumulation pattern at CPSH: this marks his fifth open-market buy in the past six months. Of his four prior CPSH purchases with measurable 90-day outcomes, all four were well-timed—stock rose after each trade. His cross-ticker track record shows 9 prior buys with a 100.00% 90-day win rate and average 90d return of +25.0%, establishing a consistent pattern of disciplined entry timing. The current share price of $3.76 sits 41.1% below the 52-week high, having declined 20.0% in the past 30 days; yet CPSH's fundamentals show annual revenue growth of +54.3% and a market cap of $67.6M. The repeated buying despite recent price weakness, combined with demonstrated timing accuracy across both ticker-specific and broader portfolios, suggests the director perceives value at current levels relative to the company's growth trajectory.

Director Cavoli Ivo James bought 1,500 shares of CPSH at $3.42 on 2025-11-13; stock down 27.5% from 52-week high but up 6.6% over 90 days.

Director Cavoli Ivo James purchased 1,500 shares at $3.42, increasing his holdings from 49.2K to 50.7K shares. The purchase follows five prior open-market buys at CPSH, with two completed transactions showing 90-day outcomes: one returned +15.1% and another returned +20.4%. Across his broader cross-ticker track record, his 8 prior buys averaged 90d return +29.2% with a 100.00% win rate. The current price of $3.40 sits near the transaction price and is down -27.5% from the 52-week high, though the stock is up +6.6% over the past 90 days. Fundamentals show revenue of $8.8M in the latest quarter, with the company reporting full-year net losses and annual revenue decline of -23.3%.

CEO Mackey bought 16,500 CPSH shares at $3.00 on Oct 8, +82.5% to holdings; 3 prior buys all posted +59-67% 90d returns

Mackey Brian T, President & CEO, purchased 16,500 shares at $3.00, expanding his position from 20,000 to 36,500 shares. His prior three purchases at CPSH (on 2025-03-17, 2025-03-18, and 2025-03-19) each delivered strong 90-day returns ranging from +59.8% to +67.7%, establishing a consistent pattern of well-timed accumulation at this ticker. This latest purchase occurs amid a 90-day price appreciation of +58.6% and coincides with four other insiders also buying within the past 14 days, signaling coordinated confidence despite company fundamentals showing annual revenue decline of -23.3% and full-year unprofitability. The repetition of the buying pattern, combined with the cluster activity and the stock's proximity to its 52-week high of $4.06, warrants attention to whether management perceives fundamental improvement ahead or is continuing a momentum-driven accumulation pattern established in March.

Director Snow buys 3,333 shares of CPSH at $3.00 (+38.7% stake), amid 4-insider cluster buy and company revenue decline of -23.3%.

Director Daniel C. Snow purchased 3,333 shares at $3.00, increasing his holdings by 38.7% to 11,941 shares total in a cluster pattern with 4 other insiders buying within 14 days. The company faces significant headwinds: annual revenue declined -23.3%, and the company posted negative full-year net income despite the latest quarter generating $8,078,657.00 in revenue. Snow's prior purchase at CPSH on 2024-03-12 returned -4.4% over 90 days, and his cross-ticker track record shows 0% success rate at the 90-day mark. The stock currently trades at $3.98, down -2.0% from its 52-week high of $4.06, but up +15.0% over 30 days, suggesting some recent momentum that may be driving the multi-insider activity.

CFO Griffith Charles Kellogg Jr bought 4,000 shares at $3.00; cluster pattern with 4 other insiders buying within 14 days

CFO Griffith Charles Kellogg Jr purchased 4,000 shares of CPSH at $3.00 on 2025-10-08, increasing his holdings by 10.6% to 41,792 shares. This open-market buy occurs within a broader cluster: 4 other insiders also bought within the past 14 days, suggesting coordinated confidence at current valuations. Notably, his prior two buys at this ticker (2024-11-15 and 2024-09-17) both showed positive 90-day returns of +42.1% and +10.5% respectively, establishing a pattern of well-timed accumulation. However, context matters: the company posted negative full-year net income and annual revenue contracted 23.3%, though the latest quarterly revenue reached $8,078,657.00 and net income was $103,833.00. The stock has risen 15.0% over 30 days and 58.6% over 90 days from depressed levels, trading near its 52-week high of $4.06 at a current price of $3.98.

Director Cavoli bought 25,000 CPSH shares at $3.00 on 2025-10-08; holdings +103.4% to 49.2K shares. Part of 4-insider cluster.

Director Ivo James Cavoli purchased 25,000 shares at $3.00, more than doubling his position to 49.2K shares post-transaction. This purchase is part of a cluster pattern in which 4 other insiders also bought within the past 14 days, suggesting coordinated conviction among the board. The stock has recovered +15.0% over the past 30 days and +58.6% over 90 days from a 52-week low of $1.39, though current price of $3.98 remains -2.0% from the 52-week high of $4.06. However, the company faces headwinds: annual revenue declined -23.3% year-over-year to $8.1M in the latest quarter, and the company was unprofitable over its most recent full fiscal year. Cavoli's prior purchases at this ticker have shown positive short-term returns (ranging 13.7% to 23.4% over 30 days), but the fundamental deterioration and negative full-year earnings warrant close monitoring of whether insider accumulation can outweigh operational challenges.

Director Hughes buys 18,333 shares of CPSH at $3.00; 4 insiders bought in past 14 days amid -23.3% revenue decline

Director Francis J Hughes Jr purchased 18,333 shares at $3.00 on 2025-10-08, increasing his holdings by 4.4% to 438,009 shares. This transaction is part of a cluster pattern: 4 other insiders also bought within the past 14 days, suggesting coordinated or momentum-driven activity at the board/management level. The purchase occurs against a backdrop of material operational stress: the company reported annual revenue growth of -23.3% and was unprofitable over its most recent full fiscal year, with latest quarterly revenue of $8,078,657 and net income of only $103,833. The stock's 30-day performance (+15.0%) and 90-day performance (+58.6%) show recent recovery, but the company's weak fundamentals (negative full-year net income) and sharp revenue contraction warrant scrutiny of whether this cluster buying reflects conviction in a turnaround or simply purchasing at depressed valuations post-decline.

Director Cavoli buys 1,500 shares at $3.03; stock up +27.4% in 30 days but company posted -23.3% annual revenue decline

Cavoli Ivo James, a director of CPS TECHNOLOGIES CORP/DE/, purchased 1,500 shares at $3.03 on 2025-08-20 and now holds 24,185 shares post-transaction. The stock has appreciated +27.4% over the past 30 days and trades near its 52-week high range, yet the company's fundamentals present a significant headwind: annual revenue growth stands at -23.3%, and the company posted a net loss over its most recent full fiscal year, with the latest quarterly revenue at $8.1M declining sharply from prior periods. This represents the insider's fifth buy transaction in a narrow 73-day window (four on 2025-08-08, one on 2025-08-11), suggesting sustained accumulation despite deteriorating financial performance. The cross-ticker track record shows a 100% 90-day win rate but a negative 30-day average return of -3.8%, and the one measurable same-ticker outcome (2025-06-18 buy) was slightly underwater at -0.7% over 30 days, leaving unclear whether this recent momentum will persist.

Director Cavoli bought 9,425 shares over 4 days at blended avg $2.79; stock up 32.3% in 30d, now at 52-week high.

Cavoli Ivo James, a director, executed 4 separate purchases totaling 9,425 shares for $26,257.91 across August 8–11, 2025, at prices ranging from $2.72 to $2.90—a blended average of $2.79. His post-transaction holdings of 22,685 shares represent a 71.1% increase from his pre-transaction holdings of 13,260 shares, constituting a material accumulation. The timing aligns with a sharp price recovery: the stock has risen 32.3% over the prior 30 days and 76.6% over the prior 90 days, now trading at $3.32, matching the 52-week high. His prior buy at this ticker (June 18, 2025) has delivered a -0.7% return at the 30-day mark, while an earlier purchase (March 17, 2025) achieved a +65.8% 90-day return. Against this backdrop, the company faces structural headwinds: revenue declined 23.3% year-over-year to $8.1M in the latest quarter, net income is underwater at negative full-year results, and the market cap remains modest at $48.2M. The director's aggressive accumulation at prices near the 52-week high—following a recent rally—occurs against fundamentals deteriorating materially, creating a disconnect between insider buying intensity and operational trends.

Director Cavoli purchases 6,260 shares of CPSH at $2.54, doubling holdings to 13,260 shares, echoing prior well-timed buy despite -23.3% revenue decline.

Cavoli Ivo James, a director, purchased 6,260 shares at $2.54 on 2025-06-18, increasing his position by 89.4% to 13,260 shares post-transaction. This mirrors his buying behavior at this ticker: his prior CPSH buy on 2025-03-17 produced a 90-day return of +65.8%, establishing a 100% win rate on CPSH (1 of 1 prior buys were well-timed). The current stock price of $2.62 reflects stock appreciation in the 30-day (+25.4%) and 90-day (+57.8%) windows following the earlier March transaction. However, context is critical: the company reported annual revenue growth of -23.3%, operates unprofitable (full-year net income was negative), and has a modest market cap of $38.1M against quarterly revenue of $7.5M. The director's reinvestment pattern—acquiring additional shares after prior gains—occurs against a backdrop of operational contraction, not expansion.